The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patients

The prospective study of denosumab for the treatment of osteoporosis in hemodialysis patients - The effect of denosumab on hemodialysis patients with osteoporosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022179

Enrollment

Registered

2016-05-02

Start date

2016-05-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Patients will be injected subcutaneously with 60 mg of denosumab every 6 months for 60 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hemodialysis patient with osteoporosis including these Criteria 1)young adult mean(YAM)<70 % 2)cCa 8.0-10.5 mg/dL

Exclusion criteria

Exclusion criteria: Patient who have the contraindication for denosumab

Design outcomes

Primary

Measure	Time frame
Change in bone mineral density(BMD) at distal radius,P1NP and TRACP-5b	—

Secondary

Measure	Time frame
Change in Ca,iP,intact-PTH and side effect	—

Countries

Japan

Contacts

Public ContactDaisuke Nagasaku

Yujinkai Medical Corporation Yujin-yamazaki Hospital Department of Intenal Medicine

dnagasaku@yujin-yamazaki.co.jp0749-23-1800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026